In summary, CAR γδ T cells offer several theoretical and practical advantages over traditional CAR αβ T cells, including MHC-independent targeting, lower GvHD risk, innate tumor recognition, broad-spectrum antitumor activity, improved resistance to immunosuppression, faster manufacturing, and potentially reduced toxicity. The gene discussed is HLA-C; the disease is neoplasm.